Literature DB >> 11568990

Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study.

H A Wojtczak1, G S Kerby, J S Wagener, S C Copenhaver, R W Gotlin, D W Riches, F J Accurso.   

Abstract

Inhaled corticosteroids are commonly used in cystic fibrosis (CF), but there are few studies evaluating their safety in young children. We, therefore, prospectively administered beclomethasone diproprionate (BDP) to 12 clinically stable young children with CF to examine the safety of this therapy with respect to adrenal suppression and airway infection. To determine potential mechanisms of corticosteroid action in CF, we also examined airway markers of inflammation before and after inhaled steroid treatment. BDP 210 microg twice a day was given via spacer for 2 months. Twelve-hour serum and urine cortisols and response to low-dose synthetic ACTH cortisol stimulation were assessed. Bronchoalveolar lavage fluid (BALF) was examined pre- and posttreatment with BDP by quantitative bacteriology and indices of airway inflammation, including levels of total neutrophils, neutrophil elastase-alpha-1 antiprotease complexes (NEAP), CA 19-9 mucin-associated antigen, interleukin-8 (IL-8), and macrophage IL-8 mRNA. Following 2 months of treatment, serum and urine cortisol levels were unchanged. Response to low-dose ACTH cortisol stimulation was not significantly decreased at 30 min. Posttreatment BALF bacterial density was not statistically different from pretreatment; however, one patient who was initially culture negative became culture-positive with Hemophilus influenzae. BALF total neutrophil counts, corrected for epithelial lining fluid dilution, were decreased to approximately one third of pretreatment values (P = 0.03). NEAP and CA 19-9 mucin-associated antigen demonstrated similar decreases. BALF IL-8 levels and macrophage IL-8 mRNA levels were not statistically changed. These findings suggest that treatment with BDP 420 microg per day for 2 months in young children with CF does not affect urine and blood cortisol, causes no decrease in adrenal reserve, and does not result in a clinically significant increase in airway infection. In addition, the fall in bronchoalveolar lavage fluid inflammatory markers following BDP suggests possible modulation of neutrophil influx into the CF airway and provides justification for further studies of inhaled corticosteroids in CF. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568990     DOI: 10.1002/ppul.1122

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  10 in total

Review 1.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

2.  Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?

Authors:  Kris De Boeck; Frans De Baets; Anne Malfroot; Kristine Desager; Françoise Mouchet; Marijke Proesmans
Journal:  Eur J Pediatr       Date:  2006-06-24       Impact factor: 3.183

3.  Dexamethasone-mediated repression of MUC5AC gene expression in human lung epithelial cells.

Authors:  Yajun Chen; Tracey J Nickola; Nancy L DiFronzo; Anamaris M Colberg-Poley; Mary C Rose
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-20       Impact factor: 6.914

4.  Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis.

Authors:  C M Gordon; E Binello; M S LeBoff; M E Wohl; C J Rosen; A A Colin
Journal:  Osteoporos Int       Date:  2006-03-16       Impact factor: 4.507

Review 5.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

6.  Glucocorticoid receptor and histone deacetylase-2 mediate dexamethasone-induced repression of MUC5AC gene expression.

Authors:  Yajun Chen; Alan M Watson; Chad D Williamson; Michael Rahimi; Chong Liang; Anamaris M Colberg-Poley; Mary C Rose
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-12       Impact factor: 6.914

Review 7.  The role of inhaled corticosteroids in the management of cystic fibrosis.

Authors:  Kristie R Ross; James F Chmiel; Michael W Konstan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

9.  Inhaled corticosteroids for cystic fibrosis.

Authors:  Ian M Balfour-Lynn; Karen Welch; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-07-04

Review 10.  Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus.

Authors:  Xin Li; Fengri Jin; Hyun Jae Lee; Choong Jae Lee
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.